musculoskeletal system disease: A disease involving the musculoskeletal system. [database_cross_reference: MONDO:DesignPattern]
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
234 |
4. Check minimum number of eventsNone |
234 |
5. Include endpointsNone |
234 |
6. Filter based on genotype QC (FinnGen only) |
234 |
Control definitions (FinnGen only)
- Control exclude
- M13_OSTEOCHONDRO
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Osteopathy in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Other disorders of bone
- Osteopathies and chondropathies
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1723 | 895 | 807 |
| Only index persons | 1430 | 752 | 678 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 67.00 | 67.82 | 66.10 |
| Only index persons | 66.54 | 67.84 | 65.10 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 234 | 127 | 107 |
| Unadjusted period prevalence (%) | 0.05 | 0.04 | 0.05 |
| Median age at first event (years) | 65.52 | 64.46 | 66.78 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 218
- Matched controls
- 2181
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M90.7*C90.0
ICD-10 Finland
Pathological fracture in multiple myeloma
+∞
106.1
93
*
H02AB02
ATC
dexamethasone; systemic
21.9
73.9
119
113
WF049
NOMESCO Finland
Radiotherapy of metastasis
43.3
71.6
89
34
N02AA05
ATC
oxycodone; systemic
18.0
71.5
129
162
C90.0
ICD-10 Finland
Multiple myeloma
187.9
66.1
66
5
M90.7
ICD-10 Finland
Fracture of bone in neoplastic disease
+∞
55.6
51
*
9732/3-C42.1
ICD-O-3
Plasma cell myeloma of bone marrow
297.7
48.1
47
*
L04AX04
ATC
lenalidomide; oral
297.7
48.1
47
*
153
Kela drug reimbursment
Lenalidomid
203.8
48.0
48
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
41.0
46.6
58
19
NF3AA
NOMESCO Finland
Femur X-ray examination
50.7
42.9
51
13
WF004
NOMESCO Finland
Palliative radiotherapy
40.7
42.6
53
17
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
21.1
41.6
63
41
M05BX04
ATC
denosumab; parenteral
20.8
39.5
60
39
L03AA02
ATC
filgrastim; parenteral
32.1
39.4
52
21
M84.4
ICD-10 Finland
Pathological fracture, not elsewhere classified
+∞
38.7
36
*
NE1AA
NOMESCO Finland
Pelvis X-ray examination
13.8
36.8
67
68
NFB60
NOMESCO Finland
Demanding prosthetic replacement of hip
71.6
36.7
41
7
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.4
35.6
138
464
Z51.5
ICD-10 Finland
Palliative care
13.7
35.3
64
64
A04AA01
ATC
ondansetron; systemic, rectal
12.4
35.0
67
75
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
17.7
31.3
50
36
329
Kela drug reimbursment
Lenalidomide
111.0
27.4
29
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
10.6
27.4
56
69
A49.9
ICD-10 Finland
Bacterial infection, unspecified
8.1
27.2
67
113
A03FA01
ATC
metoclopramide; systemic, rectal
5.8
27.0
92
242
NFR20
NOMESCO Finland
Incomplete excision of soft tissue tumour of hip or thigh
+∞
26.6
25
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
12.4
24.8
46
46
JN4BD
NOMESCO Finland
Extensive body CT
7.0
24.1
66
128
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
25.6
23.9
33
15
B03XA02
ATC
darbepoetin alfa; parenteral
22.6
23.0
33
17
ZX120
NOMESCO Finland
Intravenous
6.6
21.7
61
121
WX212
NOMESCO Finland
Femoral plexus blockade
20.6
21.6
32
18
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
10.8
21.3
42
47
WW300
NOMESCO Finland
Transfer of autologic stem cells
231.2
21.0
21
*
NFJ60
NOMESCO Finland
Internal fixation of fracture of other parts of femur with intramedullary nail
53.6
20.6
24
5
B01AB10
ATC
tinzaparin; parenteral
8.1
20.4
48
73
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
115.6
19.9
21
*
NBJ60
NOMESCO Finland
Internal fixation of fracture of shoulder or upper arm using intramedullary nail, humerus
219.1
19.9
20
*
TPH04
NOMESCO Finland
Cathetrisation of vein
4.4
19.6
87
286
WW500
NOMESCO Finland
Blood transfusion
12.1
19.6
36
35
ZX112
NOMESCO Finland
Subcutaneous
18.1
19.5
30
19
NJ3DA
NOMESCO Finland
Long bones of extremities X-ray examination
60.8
19.3
22
*
XW000
NOMESCO Finland
Bone marrow biopsy
10.9
19.1
37
40
M907, C6488
ICD-10 Finland
NA
+∞
19.0
18
*
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
109.6
18.9
20
*
393
Kela drug reimbursment
Pomalidomide
207.1
18.8
19
*
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
28.0
18.7
25
10
B01AB05
ATC
enoxaparin; parenteral
3.8
18.7
109
452
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
15.6
18.4
30
22
A04AA02
ATC
granisetron; systemic, transdermal
9.9
18.1
37
44
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
103.6
17.9
19
*
L04AX06
ATC
pomalidomide; oral
195.2
17.8
18
*
C03CA01
ATC
furosemide; systemic
3.7
17.7
103
421
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
13.2
17.7
31
27
AA1AA
NOMESCO Finland
Head X-ray examination
54.7
17.3
20
*
R4110
NOMESCO Finland
Physiotherapy
3.8
17.3
95
369
M04AA01
ATC
allopurinol; systemic
5.1
17.1
59
147
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
22.3
16.8
24
12
TPX10
NOMESCO Finland
Implantation of vascular injection port
16.0
16.8
27
19
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.5
16.3
104
450
M90.8*N25.0
ICD-10 Finland
Osteopathy in renal osteodystrophy
+∞
15.8
15
*
JN4AD
NOMESCO Finland
Body CT examination
5.9
15.1
44
89
A06AH03
ATC
naloxegol; oral
34.5
15.1
19
6
S42.3
ICD-10 Finland
Fracture of shaft of humerus
34.5
15.1
19
6
ZX090
NOMESCO Finland
Other technic of radiotherapy
10.6
15.0
29
31
WW402
NOMESCO Finland
Leucoferesis
+∞
14.7
14
*
YNB10
NOMESCO Finland
Collection of stem cells for transplant
+∞
14.7
14
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.4
14.7
40
74
1507
Kela drug reimbursment
Pomalidomide
160.3
14.6
15
*
XX3DW
NOMESCO Finland
Time consuming IT work
5.3
14.5
47
108
S72.3
ICD-10 Finland
Fracture of shaft of femur
45.9
14.3
17
*
J01MA12
ATC
levofloxacin; systemic
3.9
14.3
68
228
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
14.0
14.3
24
19
A79
ICPC
Malignancy NOS
19.2
14.1
21
12
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.9
14.1
65
212
WX402
NOMESCO Finland
General anaesthesia
4.0
14.1
63
200
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.3
13.8
38
71
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
5.4
13.8
43
94
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
27.8
13.6
18
7
A02BC02
ATC
pantoprazole; systemic
3.3
13.6
168
1104
NB6AA
NOMESCO Finland
Humerus X-ray examination
15.1
13.6
22
16
130
Kela drug reimbursment
Malignant tumour
5.3
13.3
42
93
A06AD11
ATC
lactulose; oral
4.1
13.3
57
173
M05BA02
ATC
clodronic acid; systemic
30.5
13.2
17
6
115
Kela drug reimbursment
Breast cancer
5.5
13.1
40
85
NF1AA
NOMESCO Finland
Hip X-ray examination
5.4
13.1
41
90
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
6.6
13.1
34
59
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
16.8
12.9
20
13
L03AA13
ATC
pegfilgrastim; parenteral
8.3
12.7
28
38
NF3AD
NOMESCO Finland
Femur CT
+∞
12.6
12
*
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
137.6
12.6
13
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
14.5
12.2
20
15
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.8
12.2
57
186
A28
ICPC
Limited function/disability NOS
3.8
12.2
57
186
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
11.5
12.1
22
21
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
17.7
11.9
18
11
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.2
11.7
75
308
R50.9
ICD-10 Finland
Fever, unspecified
4.1
11.6
48
140
YN1BD
NOMESCO Finland
Extensive CT examination of extremities for dose design of radiotherapy
126.4
11.5
12
*
197
Kela drug reimbursment
Sunitinib
126.4
11.5
12
*
398
Kela drug reimbursment
Ixazomib
126.4
11.5
12
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
6.2
11.4
31
57
WW200
NOMESCO Finland
Immunization
10.4
11.0
21
22
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.7
11.0
120
686
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
29.7
10.9
14
5
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
6.1
10.7
29
53
1XX32
NOMESCO Finland
NA
+∞
10.5
10
*
A11CC03
ATC
alfacalcidol; systemic
9.9
10.3
20
22
TPH07
NOMESCO Finland
Cathetrisation of artery
4.0
10.2
42
122
X59
ICD-10 Finland
Exposure to unspecified factor
3.3
10.1
58
218
L02BA03
ATC
fulvestrant; parenteral
21.2
9.9
14
7
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
57.6
9.7
11
*
JN4CD
NOMESCO Finland
Very extensive body CT
7.2
9.7
23
35
L02BA01
ATC
tamoxifen; oral
6.8
9.7
24
39
N03AX16
ATC
pregabalin; oral
2.9
9.7
68
291
ZXA00
NOMESCO Finland
Right side
2.7
9.6
78
369
L01AA03
ATC
melphalan; systemic
104.4
9.5
10
*
1505
Kela drug reimbursment
Ixazomib
104.4
9.5
10
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
7.9
9.5
21
29
L02BG04
ATC
letrozole; oral
5.2
9.5
29
62
X76
ICPC
Malignant neoplasm breast female
22.9
9.5
13
6
NEK99
NOMESCO Finland
Other operation on bone of pelvis
+∞
9.4
9
*
L01XX50
ATC
[U] ixazomib; oral
+∞
9.4
9
*
M49.5*C90.0
ICD-10 Finland
Vertebral fracture due to multiple myeloma
+∞
9.4
9
*
WZC30
NOMESCO Finland
Teaching
3.5
9.4
47
160
1501
Kela drug reimbursment
Palbociclib
38.4
9.1
11
*
192
Kela drug reimbursment
Fulvestrant
19.6
9.0
13
7
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
11.4
8.9
16
15
L01BC06
ATC
capecitabine; oral
6.7
8.9
22
36
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.6
8.8
76
369
ZX070
NOMESCO Finland
Intensity modified radiotherapy
14.9
8.8
14
10
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
14.9
8.8
14
10
1502
Kela drug reimbursment
Cabozantinib
52.1
8.7
10
*
3012
Kela drug reimbursment
Cabozantinib
52.1
8.7
10
*
WX2DD
NOMESCO Finland
Low-dose CT of skeleton in whole body
52.1
8.7
10
*
TK800
NOMESCO Finland
Hemodialysis
9.6
8.7
17
19
ZX080
NOMESCO Finland
Image guided radiotherapy
10.7
8.7
16
16
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
8.6
47
169
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
8.4
8.6
18
23
TKC20
NOMESCO Finland
Catheterisation of bladder
4.6
8.5
29
70
N02AX02
ATC
tramadol; systemic, rectal
2.4
8.5
107
633
J05AB01
ATC
aciclovir; systemic
2.8
8.4
60
260
M907, C61
ICD-10 Finland
NA
+∞
8.4
8
*
L01XE26
ATC
[U] cabozantinib; oral
+∞
8.4
8
*
C50.4
ICD-10 Finland
Malignant neoplasm: Upper-outer quadrant of breast
18.0
8.2
12
7
394
Kela drug reimbursment
Palbociclib
34.8
8.1
10
*
L01XE33
ATC
[U] palbociclib; oral
34.8
8.1
10
*
J01MA14
ATC
moxifloxacin; systemic
4.0
8.1
32
89
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
5.3
8.1
24
50
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
9.0
8.0
16
19
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
5.7
7.9
22
42
N02BE01
ATC
paracetamol; systemic, rectal
3.3
7.9
197
1616
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.6
7.8
62
285
5BA08
NOMESCO Finland
NA
46.7
7.8
9
*
AA1BD
NOMESCO Finland
Extensive CT of head and brain
8.5
7.7
16
20
N18.0
ICD-10 Finland
End-stage renal disease
12.5
7.7
13
11
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
19.2
7.7
11
6
WX320
NOMESCO Finland
Spinalanesthesy
2.6
7.7
65
308
J05AB11
ATC
valaciclovir; oral
3.2
7.7
42
151
NE1AD
NOMESCO Finland
Pelvis and hip bones CT examination
7.6
7.6
17
24
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
26.1
7.6
10
*
WX002
NOMESCO Finland
Sedation and analgesia
2.7
7.6
58
260
M80.9
ICD-10 Finland
Unspecified osteoporosis with pathological fracture
82.8
7.5
8
*
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
+∞
7.3
7
*
158
Kela drug reimbursment
Everolimus
+∞
7.3
7
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
6.4
7.2
18
30
159
Kela drug reimbursment
Pazopanib
31.1
7.2
9
*
8312/3-C64.9
ICD-O-3
Renal cell carcinoma, NOS, of kidney, NOS
31.1
7.2
9
*
L28
ICPC
Limited function/disability (L)
2.8
7.2
50
211
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
9.3
7.2
14
16
HAC20
NOMESCO Finland
Total mastectomy
5.8
7.1
19
35
WX200
NOMESCO Finland
Interscalenous plexus blockade
8.0
7.0
15
20
HA1AA
NOMESCO Finland
X-ray mammography
3.9
7.0
28
79
127
Kela drug reimbursment
Transplant complication
9.8
6.9
13
14
A12AA04
ATC
calcium carbonate; oral
11.5
6.9
12
11
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
4.6
6.9
23
55
NFJ62
NOMESCO Finland
Internal fixation of fracture of other parts of femur with plate
41.4
6.8
8
*
C90.2
ICD-10 Finland
Extramedullary plasmacytoma
41.4
6.8
8
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.3
6.7
24
61
L01AA01
ATC
cyclophosphamide; systemic
23.4
6.7
9
*
S72.4
ICD-10 Finland
Fracture of lower end of femur
23.4
6.7
9
*
XF400
NOMESCO Finland
ECG with 12 standard connections
2.7
6.7
50
219
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.0
6.5
37
137
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.6
6.5
29
90
N17.9
ICD-10 Finland
Acute renal failure, unspecified
5.5
6.5
18
35
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
71.9
6.5
7
*
L01XE04
ATC
[U] sunitinib; oral
71.9
6.5
7
*
KAC10
NOMESCO Finland
Total nephrectomy with capsule
14.9
6.5
10
7
Z49.1
ICD-10 Finland
Extracorporeal dialysis
9.7
6.4
12
13
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
11.5
6.4
11
10
AA3AI
NOMESCO Finland
Cone beam CT of facial bones
18.7
6.3
9
5
L02BB04
ATC
enzalutamide; oral
18.7
6.3
9
5
NK6AN
NOMESCO Finland
Total body bone isotope imaging
5.7
6.3
17
32
M907, C5041
ICD-10 Finland
NA
+∞
6.3
6
*
G62.0
ICD-10 Finland
Drug-induced polyneuropathy
+∞
6.3
6
*
M907, C795
ICD-10 Finland
NA
+∞
6.3
6
*
S72.0
ICD-10 Finland
Fracture of neck of femur
5.5
6.2
17
33
V03AE01
ATC
polystyrene sulfonate; oral
10.5
6.1
11
11
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.8
6.1
39
157
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
68
55
17.02
72.51
20.0
5.7
57.2
156.4
mg/l
0.40
57
44
68
55
17.02
72.51
20.0
5.7
43.9
29.4
mg/l
0.43
57
44
67
55
16.67
70.76
19.9
5.5
6.8
3.6
ratio
—
5
6
120
296
7.27
51.55
8.1
3.8
0.8
0.8
mmol/l
0.60
115
282
43
31
16.77
48.05
7.3
7.9
615.3
189.0
iu/ml
—
8
6
47
65
8.80
33.54
14.7
3.0
1.5
0.6
g/l
0.90
42
58
49
75
8.00
32.03
15.1
2.3
—
—
—
0
0
49
75
8.00
32.03
15.1
2.3
3.5
3.6
g/l
0.18
34
56
49
75
8.00
32.03
15.1
2.3
7.3
7.5
g/l
0.29
37
58
46
68
8.18
30.94
15.6
2.5
9.1
10.4
g/l
0.96
38
63
46
68
8.18
30.94
16.0
2.5
3.2
3.1
g/l
0.51
35
56
98
299
4.92
30.68
2.9
1.9
—
—
—
0
0
79
218
4.96
27.67
2.5
1.8
—
—
—
0
0
79
221
4.89
27.16
2.6
1.8
—
—
—
0
0
143
635
4.22
26.07
16.8
3.1
2.3
2.4
mmol/l
0.44
134
548
57
129
5.52
24.99
2.3
1.4
—
—
—
0
0
179
963
4.65
24.18
29.6
6.5
1.2
1.2
mmol/l
0.54
148
815
33
50
7.52
21.46
2.3
1.7
—
—
—
0
0
20
15
14.49
21.35
1.2
1.3
—
—
—
0
0
29
39
8.35
20.85
10.2
3.0
81.4
32.4
u/ml
0.52
29
39
93
350
3.75
20.62
8.4
2.9
2.5
2.5
mmol/l
1.95
88
307
183
1076
4.22
19.99
43.0
9.9
3.9
4.1
e9/l
0.55
168
946
29
41
7.93
19.98
1.9
1.7
—
—
—
0
0
32
51
7.11
19.84
2.2
1.8
—
—
—
0
0
33
55
6.82
19.63
1.6
1.3
—
—
—
0
0
104
438
3.47
19.12
5.0
2.3
—
—
—
0
0
74
256
3.77
18.34
4.8
2.2
21.3
23.9
%
0.82
65
216
23
27
9.34
18.33
1.3
1.6
—
—
—
0
0
117
545
3.29
18.00
5.5
2.9
0.4
0.4
e6/l
0.06
95
397
23
28
9.00
17.82
1.9
1.3
—
—
—
0
0
62
195
3.97
17.56
5.5
3.2
—
—
—
0
0
19
18
11.40
17.55
3.5
3.6
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
31
57
6.12
16.68
3.7
10.1
0.3
0.4
u/ml
0.85
17
30
25
37
7.45
16.48
1.4
1.3
—
—
—
0
0
25
37
7.45
16.48
1.4
1.3
—
—
—
0
0
51
149
4.10
15.90
9.5
3.6
104.5
71.5
ng/l
1.36
42
130
36
81
5.07
15.56
11.0
4.1
23.8
24.2
mmol/l
0.28
36
75
61
205
3.67
15.55
5.9
6.9
5.1
5.1
kpa
0.15
56
193
79
316
3.26
15.27
4.7
2.7
1.7
2.0
e6/l
0.16
54
172
152
879
3.08
15.20
8.9
3.7
—
—
—
0
0
61
210
3.58
14.95
5.9
6.8
1.3
1.3
mmol/l
0.01
47
167
128
684
2.92
14.63
5.7
3.0
—
—
—
0
0
52
165
3.77
14.35
10.2
3.6
1.7
2.2
mmol/l
0.33
45
132
22
33
7.25
14.29
1.6
1.5
—
—
—
0
0
24
41
6.41
13.82
2.3
1.4
—
—
—
0
0
103
504
2.86
13.67
9.5
2.8
5110.8
11398.9
umol/l
0.56
97
418
78
333
3.01
13.24
4.8
2.5
1.2
1.0
e6/l
0.19
53
186
20
30
7.20
12.96
2.0
1.5
—
—
—
0
0
19
28
7.30
12.49
2.0
1.5
397.4
288.0
u/ml
0.28
12
17
15
17
9.36
12.13
1.1
1.2
—
—
—
0
0
19
31
6.58
11.38
4.3
3.5
3.9
4.8
e9/l
0.84
19
31
19
32
6.37
11.04
4.5
4.1
60.0
58.9
%
0.14
19
32
13
14
9.77
10.86
1.5
1.5
—
—
—
0
0
56
222
3.00
10.61
6.3
2.8
15.6
8.2
umol/l
0.42
45
194
24
55
4.75
10.06
9.6
3.6
1.5
1.6
mg/l
0.13
24
49
13
5
27.37
9.92
1.6
1.2
—
—
—
0
0
12
14
8.98
9.43
1.2
1.1
—
—
—
0
0
14
20
7.38
9.39
2.9
2.0
—
—
—
0
0
18
34
5.65
9.32
2.7
2.2
14.2
16.2
%
—
10
15
55
233
2.78
9.14
6.3
4.3
6.4
27.7
ug/l
0.63
48
196
32
99
3.59
9.01
1.5
1.3
—
—
—
0
0
14
21
7.03
9.00
2.9
2.0
—
—
—
0
0
12
17
7.39
8.07
1.5
1.5
—
—
—
0
0
169
1236
2.32
7.71
6.4
4.2
2945.3
174.6
e6/l
—
7
24
18
43
4.45
7.15
2.2
1.2
—
—
—
0
0
13
23
5.93
7.15
3.2
2.4
33.5
32.6
pg
0.56
13
23
19
49
4.13
6.86
1.6
1.9
—
—
—
0
0
31
112
3.04
6.79
7.6
6.3
2.3
2.1
mmol/l
0.06
24
87
10
14
7.42
6.75
1.1
1.0
—
—
—
0
0
10
7
14.84
6.45
1.3
1.7
—
—
—
0
0
12
22
5.70
6.35
3.2
2.6
—
—
—
0
0
71
397
2.13
6.17
3.1
2.0
2.2
1.2
mg/l
0.66
62
318
68
375
2.15
6.12
5.7
3.8
148.2
143.8
ng/l
0.02
56
301
10
16
6.48
6.00
1.5
1.2
—
—
—
0
0
161
1923
0.48
5.98
4.7
5.3
2.7
2.8
mmol/l
0.21
141
1770
18
50
3.82
5.88
4.6
9.2
8.5
8.4
kpa
0.07
18
43
114
767
1.95
5.86
4.7
2.6
270.1
130.4
ug/l
4.26
107
699
158
1894
0.49
5.76
4.5
4.7
4.6
4.7
mmol/l
0.47
138
1753
30
117
2.79
5.73
2.2
1.8
—
—
—
0
0
148
1811
0.50
5.71
7.1
6.0
41.8
40.3
mmol/mol
0.81
137
1675
112
755
1.93
5.67
3.6
2.2
75.2
76.9
nmol/l
0.25
104
661
75
442
2.03
5.60
2.3
1.9
3.5
3.3
mg/l
0.24
60
373
19
57
3.54
5.57
2.2
2.7
—
—
—
0
0
12
25
5.01
5.56
1.2
1.1
—
—
—
0
0
8
5
16.48
5.45
1.1
1.0
—
—
—
0
0
17
48
3.74
5.43
7.4
3.9
24.7
25.6
mmol/l
0.27
17
37
74
439
2.00
5.40
1.7
1.5
15.9
21.7
nmol/l
3.90
64
364
158
1881
0.51
5.25
4.4
4.7
1.3
1.5
mmol/l
3.87
138
1727
41
197
2.31
5.10
5.4
2.4
37.9
32.6
u/l
0.31
33
171
11
23
4.97
5.07
1.8
1.5
—
—
—
0
0
92
603
1.87
4.91
5.7
2.3
50.4
57.3
u/l
1.16
86
551
97
660
1.80
4.51
7.4
3.0
36.8
30.4
u/l
0.80
91
629
11
27
4.23
4.21
1.8
1.5
—
—
—
0
0
155
1824
0.56
4.14
4.5
4.2
1.5
1.3
mmol/l
2.25
137
1665
11
28
4.07
4.02
1.6
1.4
1.7
1.5
mmol/l
0.38
11
28
14
43
3.40
3.97
1.4
1.3
—
—
—
0
0
12
34
3.67
3.82
1.8
1.5
—
—
—
0
0
6
5
12.26
3.78
2.2
1.4
—
—
—
0
0
7
9
7.97
3.58
4.7
2.2
—
—
—
0
0
7
9
7.97
3.58
3.9
2.2
—
—
—
0
0
7
9
7.97
3.58
1.4
1.1
—
—
—
0
0
7
9
7.97
3.58
3.9
2.2
—
—
—
0
0
8
13
6.33
3.53
2.0
2.6
—
—
—
0
0
7
10
7.18
3.38
4.0
2.1
—
—
—
0
0
7
10
7.18
3.38
4.0
2.1
—
—
—
0
0
7
10
7.18
3.38
4.0
2.1
—
—
—
0
0
7
10
7.18
3.38
1.4
1.1
—
—
—
0
0
7
10
7.18
3.38
4.0
2.1
—
—
—
0
0
6
7
8.76
3.28
1.0
1.0
—
—
—
0
0
7
11
6.52
3.21
2.6
1.6
—
—
—
0
0
7
11
6.52
3.21
2.6
1.6
—
—
—
0
0
7
11
6.52
3.21
1.4
1.3
—
—
—
0
0
9
20
4.64
3.14
1.3
1.5
24.9
15.3
ug/l
—
9
20
8
16
5.14
3.08
2.4
3.5
—
—
—
0
0
7
12
5.97
3.04
1.1
1.2
12.1
12.3
umol/l
—
7
12
9
21
4.41
3.02
6.6
2.3
109.4
80.7
u/ml
—
9
21
7
13
5.51
2.89
1.3
1.0
68.7
375.0
u/l
—
7
7
102
772
1.57
2.85
2.5
2.0
92.2
96.8
pmol/l
0.39
65
382
9
23
4.03
2.80
2.6
4.3
—
—
—
0
0
55
360
1.69
2.75
2.4
1.7
1176.9
1192.7
nmol/l
0.04
42
267
166
1864
0.62
2.61
5.0
4.7
6.0
6.0
mmol/l
0.03
148
1708
5
7
7.27
2.56
2.4
1.4
—
—
—
0
0
97
740
1.53
2.55
5.8
3.6
27.3
36.3
ng/l
0.61
82
528
80
585
1.56
2.54
5.2
3.3
1348.1
901.5
ng/l
0.69
70
499
20
96
2.18
2.51
2.0
3.4
678.4
1549.2
u/ml
0.26
14
83
25
136
1.94
2.28
2.1
2.2
5.7
14.1
nmol/l
4.66
20
126
7
18
3.97
2.27
4.0
2.0
—
—
—
0
0
7
18
3.97
2.27
4.0
2.0
—
—
—
0
0
7
18
3.97
2.27
4.0
2.0
—
—
—
0
0
9
29
3.19
2.25
1.3
1.6
—
—
—
0
0
15
67
2.32
2.23
4.1
1.9
—
—
—
0
0
5
9
5.65
2.22
3.2
1.6
—
—
—
0
0
5
9
5.65
2.22
3.2
1.6
—
—
—
0
0
163
1423
1.48
2.01
5.1
4.1
28.1
12.2
mm/h
9.40
150
1288
11
45
2.52
1.96
2.1
1.5
—
—
—
0
0
5
11
4.62
1.95
2.2
1.4
—
—
—
0
0
5
11
4.62
1.95
1.6
2.5
—
—
—
0
0
5
12
4.23
1.83
1.4
1.2
—
—
—
0
0
12
242
0.47
1.83
4.3
4.6
36.0
32.5
%
—
6
158
111
914
1.41
1.82
4.5
3.5
0.0
0.0
estimate
0.00
37
172
13
60
2.24
1.81
2.6
1.8
—
—
—
0
0
9
36
2.56
1.76
1.1
1.4
—
—
—
0
0
41
279
1.57
1.75
1.3
1.5
—
—
—
0
0
7
157
0.43
1.62
1.6
1.8
—
—
—
0
0
27
170
1.66
1.57
2.2
2.1
4.4
7.4
ug/l
0.84
18
155
110
921
1.37
1.56
6.6
4.9
0.0
0.0
estimate
0.00
36
175
111
933
1.36
1.53
4.5
3.6
0.0
0.0
estimate
0.00
34
165
5
15
3.38
1.53
1.2
2.0
—
—
—
0
0
5
15
3.38
1.53
1.2
2.0
—
—
—
0
0
7
27
2.64
1.52
2.6
1.6
—
—
—
0
0
7
27
2.64
1.52
2.6
1.6
—
—
—
0
0
7
27
2.64
1.52
2.6
1.6
—
—
—
0
0
7
27
2.64
1.52
2.6
1.6
—
—
—
0
0
7
27
2.64
1.52
2.6
1.6
—
—
—
0
0
7
28
2.54
1.46
2.6
1.6
—
—
—
0
0
5
16
3.17
1.44
1.4
1.8
—
—
—
0
0
10
47
2.18
1.35
1.1
1.3
—
—
—
0
0
16
264
0.58
1.31
1.4
1.4
—
—
—
0
0
185
1711
1.39
1.23
56.4
15.2
35.9
39.7
%
10.69
123
1233
6
26
2.34
1.19
1.0
1.2
—
—
—
0
0
10
50
2.04
1.18
1.2
1.6
—
0.1
—
0
9
10
52
1.96
1.08
1.0
1.1
—
—
—
0
0
200
2090
0.70
1.03
78.3
20.5
4.0
4.5
e12/l
24.98
194
2027
9
47
1.95
1.03
1.1
1.3
—
—
—
0
0
14
219
0.62
0.96
24.9
6.9
—
—
—
0
0
41
518
0.75
0.92
4.7
4.3
30.6
22.4
%
0.61
23
235
10
58
1.76
0.81
1.1
1.3
—
—
—
0
0
164
1744
0.80
0.79
6.7
4.7
2.1
2.6
mu/l
0.35
151
1573
5
24
2.11
0.75
1.6
1.3
—
—
—
0
0
10
60
1.70
0.73
1.6
1.1
—
—
—
0
0
10
60
1.70
0.73
1.6
1.1
—
—
—
0
0
57
485
1.23
0.65
4.4
3.6
0.0
0.0
estimate
0.00
33
167
14
96
1.49
0.63
4.6
2.5
0.9
1.2
%
1.30
14
96
5
30
1.68
0.62
1.0
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.2
—
—
—
0
0
0
22
0.00
0.59
0.0
1.2
—
—
—
0
0
0
23
0.00
0.58
0.0
1.2
—
—
—
0
0
0
23
0.00
0.58
0.0
1.2
—
—
—
0
0
0
23
0.00
0.58
0.0
1.2
—
—
—
0
0
26
326
0.77
0.56
1.2
1.2
1.1
13.5
u/ml
—
6
113
20
151
1.35
0.56
4.7
3.3
52.9
60.8
ml/min/173m2
—
7
67
15
108
1.42
0.54
1.1
1.2
163.9
150.2
iu/ml
—
7
43
16
210
0.74
0.49
2.3
2.0
1.6
1.5
%
0.18
11
182
120
1279
0.87
0.45
4.1
3.0
71.3
48.9
u/l
1.80
110
1182
0
15
0.00
0.41
0.0
1.0
—
548.6
—
0
10
0
15
0.00
0.41
0.0
1.1
—
40.4
—
0
10
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
7
103
0.67
0.40
1.0
1.0
—
—
—
0
0
196
1903
1.18
0.39
61.1
13.5
26.7
23.5
mg/l
0.91
189
1509
76
695
1.14
0.38
4.9
3.6
—
—
—
0
0
196
2010
0.85
0.37
65.6
16.4
94.0
77.8
umol/l
2.61
196
2010
9
123
0.72
0.36
2.3
1.8
—
—
—
0
0
12
91
1.34
0.34
1.8
2.6
39.1
40.9
u/l
0.10
12
82
12
94
1.29
0.28
1.7
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.9
—
—
—
0
0
0
12
0.00
0.21
0.0
2.9
—
—
—
0
0
113
1085
1.08
0.21
3.3
2.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
35
380
0.91
0.17
3.0
3.1
1.2
0.8
ug/l
0.79
26
248
140
1436
0.94
0.16
6.6
3.8
14.8
14.7
pmol/l
0.07
132
1284
9
110
0.81
0.13
1.9
1.7
—
—
—
0
0
5
44
1.14
0.10
1.0
1.1
—
3.6
—
0
7
184
1818
1.06
0.09
54.1
13.0
74.8
79.2
ml/min/173m2
1.39
168
1490
199
1975
1.05
0.06
59.5
16.0
4.0
4.0
mmol/l
0.50
194
1918
40
409
0.97
0.02
1.4
1.2
1.7
1.2
u/ml
—
6
109
33
337
0.98
0.01
1.2
1.2
42.2
40.5
iu/ml
—
6
109
64
639
1.00
0.00
7.1
4.8
6.1
2.7
ug/l
0.83
55
573
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
20.3
—
0
6
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
7.1
—
0
5
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
3.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
10.2
—
0
7
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
4.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
5
51
0.98
0.00
1.0
1.2
—
31.1
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint M13_OSTEOPATHYINOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_OSTEOPATHYINOTH | 9.092 [6.48, 12.75] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.114 |
During the follow-up period (1.1.1998 — 31.12.2019), 430 out of 733 females with M13_OSTEOPATHYINOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_OSTEOPATHYINOTH | 7.116 [4.53, 11.17] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 356 out of 636 males with M13_OSTEOPATHYINOTH died.
Mortality risk
Mortality risk for people of age
years, who have M13_OSTEOPATHYINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.763% | 1.031% |
| 5 | 4.847% | 6.694% |
| 10 | 12.775% | 16.411% |
| 15 | 22.181% | 29.36% |
| 20 | 35.371% | 45.528% |
Relationships between endpoints
↥Index endpoint: M13_OSTEOPATHYINOTH – Osteopathy in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data